Clinical Study of NKG2D CAR-NK Combined with PD-1 Monoclonal Antibody in the Treatment of ATC

Zhejiang Provincial People's Hospital

Status and phase: Not yet enrolling; Phase 2; Phase 1

Conditions: Anaplastic Throid Carcinoma

Treatments: Drug: NKG2D CAR-NK with PD-1 Antibody

Study type: Interventional

Funder types: Other

Identifiers

NCT06856278

CAR-NK GeT

Details and patient eligibility

About

The patients with anaplastic thyroid cancer were treated with CAR-NK immune cells combined with PD-1 monoclonal antibody, and the safety and tolerability of the patients were observed and evaluated.

Enrollment: 30 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Age 18-75 years (including boundary values), male or female.
2. Be diagnosed with anaplastic thyroid cancer histopathologically with a measurable lesion≥1cm.
3. Liver and kidney function is good, and can tolerate treatment.
4. Be able to cooperate with the completion of treatment and follow-up work.
5. No other systemic diseases, including other malignancies.

Exclusion criteria

1. Need to breastfeed the baby or have fertility needs；
2. Immune system diseases;
3. Diseases of the blood system;
4. Mental system diseases;
5. Interstitial pneumonia, lung disease, etc.;
6. Failure to follow rules of this study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

30 participants in 1 patient group

treated with CAR-NK immune cells combined with PD-1 monoclonal antibody.

Experimental group

Treatment:

Drug: NKG2D CAR-NK with PD-1 Antibody